Related Experiment Video
Updated: Aug 22, 2025
08:17
Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
Published on: February 23, 2024
4.5K
Identification of PMD subgroups using a myelination score for PMD.
Inga Harting1, Sven F Garbade2, Stefan D Rosendaal3
1Department of Neuroradiology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 60120, Heidelberg, Germany.
Summary
A new Pelizaeus-Merzbacher disease (PMD) myelination score effectively differentiates patient subgroups and controls. This tool aids in assessing disease severity and monitoring treatment efficacy for hypomyelinating leukodystrophy.
Area of Science:
- Neurology
- Radiology
- Genetics
Background:
- Pelizaeus-Merzbacher disease (PMD) is a hypomyelinating leukodystrophy with a broad clinical spectrum.
- Emerging treatments necessitate standardized methods for grading PMD severity and progression.
Purpose of the Study:
- To develop and validate a novel myelination scoring system for Pelizaeus-Merzbacher disease.
- To enable accurate stratification of patients and objective assessment of disease progression.
Main Methods:
- A myelination score was developed using 15 anatomic sites on T2- and T1-weighted MRI scans.
- The score was validated in 328 controls and 28 PMD patients across various subtypes.
- Interrater variability, scoring practicality, and discriminatory power were key selection criteria for score items.
Main Results:
- The developed score, comprising 8 T2- and 5 T1-weighted imaging items, successfully distinguished between PMD patients and controls, and among patient subgroups.
- Severely affected patients (connatal, transitional) showed minimal myelin and early loss, while classic PMD patients had deficient myelin.
- Ongoing myelination was observed during childhood in classic and intermediate PMD cases, with atrophy increasing with age.
Conclusions:
- The proposed PMD myelination score facilitates patient stratification and standardized follow-up assessments.
- The score is crucial for evaluating treatment efficacy, considering myelin loss in severe/PLP0 cases and myelination progression in classic/intermediate PMD.
